Free Cash Flow per Share: A measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis. Calculated as: Free Cash Flow / Weighted Average Shares Outstanding (Diluted)
Altamira Therapeutics Ltd. (CYTO) had Free Cash Flow per Share of $-26.10 for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
-- |
|
$-4.31M |
|
-- |
|
-- |
|
$6.59M |
|
$-6.59M |
|
$-1.51M |
|
$-8.10M |
|
$-8.10M |
|
$-8.10M |
|
$-8.10M |
|
$-4.31M |
|
$-8.10M |
|
$-6.59M |
|
$-6.46M |
|
0.49M |
|
0.49M |
|
$-8.78 |
|
$-8.78 |
|
Balance Sheet Financials | |
$1.36M |
|
$0.00M |
|
$7.21M |
|
$8.57M |
|
$0.99M |
|
-- |
|
$0.39M |
|
$1.38M |
|
$7.19M |
|
$2.86M |
|
$7.19M |
|
1.48M |
|
Cash Flow Statement Financials | |
$-12.82M |
|
$1.61M |
|
$11.83M |
|
$0.02M |
|
$0.69M |
|
$0.67M |
|
$0.42M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
1.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-12.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-112.56% |
|
-283.43% |
|
-94.49% |
|
-112.56% |
|
$4.87 |
|
Free Cash Flow per Share |
$-26.10 |
$-26.10 |